Table 1.
Patient characteristics, n = 40
| |
Aromatase inhibitor ( n = 28) |
Trastuzumab ( n = 12) |
||
|---|---|---|---|---|
| n (%) |
Median (min, max) |
n (%) |
Median (min, max) |
|
| Age, years |
58 (35, 83) |
48 (38, 71) |
||
| Postmenopausal |
21 (75%) |
9 (75%) |
||
| ER positive |
28 (100%) |
6 (50%) |
||
| PgR positive |
26 (93%) |
6 (50%) |
||
| HER2 |
|
|
||
| Negative |
25 (89%) |
0 (0%) |
||
| Positive |
0 (0%) |
12 (100%) |
||
| Equivocal/not done |
3 (11%) |
0 (0%) |
||
| Disease status |
|
|
|
|
| Newly diagnosed |
17 (61%) |
5 (42%) |
||
| Recurrent |
11(39%) |
7 (58%) |
||
| Disease stage |
|
|
|
|
| Stage I-III (newly diagnosed) |
14 (50%) |
3 (25%) |
||
| Metastatic (newly diagnosed) |
3 (11%) |
2 (17%) |
||
| Metastatic (recurrent, newly stage IV) |
5 (18%) |
5 (41%) |
||
| Metastatic (recurrent stage IV) |
6 (21%) |
2 (17%) |
||
| Histology |
|
|
|
|
| Ductal |
14 (50%) |
9 (75%) |
||
| Lobular |
9 (32%) |
1 (8%) |
||
| Ductal and lobular |
2 (7%) |
0 (0%) |
||
| Unknown |
3 (11%) |
2 (17%) |
||
| PET index lesion |
|
|
|
|
| Breast |
16 (57%) |
5 (41%) |
||
| Nodal/soft tissue |
6 (21%) |
3 (25%) |
||
| Bone |
1 (4%) |
2 (17%) |
||
| Visceral | 5 (18%) | 2 (17%) | ||